Diamonds and Dogs


Jazz Pharmaceuticals (JAZZ) is all jazzed up. The biotech drug maker jumped 11% even as a generic version to their drug to treat daytime sleepiness and cataplexy in narcolepsy patient receives FDA approval. On the plus side for Jazz, the FDA also approved a petition from Jazz that would prevent the generic from using a "skinny label." A skinny label would allow the company to carve out information related to drug-drug interactions between sodium oxybate (Xyrem) and divalproex sodium, a drug to treat seizures.

Target (TGT) misses the mark once again.  Target dropped 5.7% after their November-December same-store sales fell 1.3%. One bright spot, online sales grew 30%. But total sales declined 4.9%, reflecting the sale of their pharmacy and clinic business in 2015. Looks like Amazon ate another retailer.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.